Literature DB >> 19464255

Distinct HDL subclasses present similar intrinsic susceptibility to oxidation by HOCl.

Sandrine Chantepie1, Ernst Malle, Wolfgang Sattler, M John Chapman, Anatol Kontush.   

Abstract

The heme protein myeloperoxidase (MPO) functions as a catalyst for lipoprotein oxidation. Hypochlorous acid (HOCl), a potent two-electron oxidant formed by the MPO-H(2)O(2)-chloride system of activated phagocytes, modifies antiatherogenic high-density lipoprotein (HDL). The structural heterogeneity and oxidative susceptibility of HDL particle subfractions were probed with HOCl. All distinct five HDL subfraction were modified by HOCl as demonstrated by the consumption of tryptophan residues and free amino groups, cross-linking of apolipoprotein AI, formation of HOCl-modified epitopes, increased electrophoretic mobility and altered content of unsaturated fatty acids in HDL subclasses. Small, dense HDL3 were less susceptible to oxidative modification than large, light HDL2 on a total mass basis at a fixed HOCl:HDL mass ratio of 1:32, but in contrast not on a particle number basis at a fixed HOCl:HDL molar ratio of 97:1. We conclude that structural and physicochemical differences between HDL subclasses do not influence their intrinsic susceptibility to oxidative attack by HOCl.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464255      PMCID: PMC3070237          DOI: 10.1016/j.abb.2009.05.005

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  43 in total

1.  Kinetics of tryptophan oxidation in plasma lipoproteins by myeloperoxidase-generated HOCl.

Authors:  A Jerlich; M Hammel; F Nigon; M J Chapman; R J Schaur
Journal:  Eur J Biochem       Date:  2000-07

2.  The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction.

Authors:  Zhiping Wu; Matthew A Wagner; Lemin Zheng; John S Parks; Jacinto M Shy; Jonathan D Smith; Valentin Gogonea; Stanley L Hazen
Journal:  Nat Struct Mol Biol       Date:  2007-08-05       Impact factor: 15.369

3.  Effect of hypochlorite (HOCl)-modified low density lipoproteins and high density lipoproteins on platelet function.

Authors:  C Opper; G Schüssler; W Sattler; E Malle
Journal:  Platelets       Date:  1998       Impact factor: 3.862

4.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

Authors:  E Nobécourt; S Jacqueminet; B Hansel; S Chantepie; A Grimaldi; M J Chapman; A Kontush
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

5.  Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages.

Authors:  Lemin Zheng; Megan Settle; Gregory Brubaker; Dave Schmitt; Stanley L Hazen; Jonathan D Smith; Michael Kinter
Journal:  J Biol Chem       Date:  2004-10-21       Impact factor: 5.157

6.  Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues.

Authors:  K Oörni; M O Pentikäinen; A Annila; P T Kovanen
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

7.  Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies.

Authors:  E Malle; L Hazell; R Stocker; W Sattler; H Esterbauer; G Waeg
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-07       Impact factor: 8.311

8.  The oxidant hypochlorite (OCl-), a product of the myeloperoxidase system, degrades articular cartilage proteoglycan aggregate.

Authors:  M Katrantzis; M S Baker; C J Handley; D A Lowther
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

Review 9.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

10.  Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.

Authors:  Maryse Guerin; Pascal Egger; Céline Soudant; Wilfried Le Goff; Arie van Tol; Reynald Dupuis; M John Chapman
Journal:  Atherosclerosis       Date:  2002-08       Impact factor: 5.162

View more
  4 in total

1.  The pattern of apolipoprotein A-I lysine carbamylation reflects its lipidation state and the chemical environment within human atherosclerotic aorta.

Authors:  Shawna Battle; Valentin Gogonea; Belinda Willard; Zeneng Wang; Xiaoming Fu; Ying Huang; Linda M Graham; Scott J Cameron; Joseph A DiDonato; John W Crabb; Stanley L Hazen
Journal:  J Biol Chem       Date:  2022-03-15       Impact factor: 5.486

2.  Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F.

Authors:  C Roger White; Geeta Datta; Amanda K W Buck; Manjula Chaddha; Gautam Reddy; Landon Wilson; Mayakonda N Palgunachari; Mohammad Abbasi; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2012-05-15       Impact factor: 5.922

3.  Effect of HDL composition and particle size on the resistance of HDL to the oxidation.

Authors:  Nakanishi Shuhei; Sanni Söderlund; Matti Jauhiainen; Marja-Riitta Taskinen
Journal:  Lipids Health Dis       Date:  2010-09-23       Impact factor: 3.876

4.  VPO1 mediates ApoE oxidation and impairs the clearance of plasma lipids.

Authors:  Youfeng Yang; Zehong Cao; Ling Tian; W Timothy Garvey; Guangjie Cheng
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.